Breaking News
Get 55% Off 0
🎈 Up Big Today: Find today's biggest gainers with our free screener
Try Stock Screener
Close

Regeneron Pharmaceuticals Inc (REGN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
699.000 -21.000    -2.92%
13/12 - Closed. Currency in EUR
Type:  Equity
Market:  Austria
ISIN:  US75886F1075 
  • Volume: 11
  • Bid/Ask: 697.800 / 700.200
  • Day's Range: 699.000 - 708.600
Regeneron Pharma 699.000 -21.000 -2.92%

NASDAQ:REGN Financials

 
Explore the NASDAQ:REGN financials. Find the Regeneron Pharma financial statements for a comprehensive overview of the company’s financial health. This summary highlights critical numbers from key financial reports, including the Regeneron Pharma annual report, the income statement, balance sheet, and cash flow statement. Gain deeper insights with financial ratios that assess the company's performance and stability. Users can customize their view by selecting data from four periods of either annual or quarterly information, making it easy to track the financial performance of Regeneron Pharma over time.

Regeneron Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2024. For the third quarter, the company reported revenue was USD 3,720.7 million compared to USD 3,362.7 million a year ago. Net income was USD 1,340.6 million compared to USD 1,007.8 million a year ago. Basic earnings per share from continuing operations was USD 12.4 compared to USD 9.48 a year ago. Diluted earnings per share from continuing operations was USD 11.54 compared to USD 8.89 a year ago. For the nine months, revenue was USD 10,412.8 million compared to USD 9,682.9 million a year ago. Net income was USD 3,494.9 million compared to USD 2,794 million a year ago. Basic earnings per share from continuing operations was USD 32.36 compared to USD 26.16 a year ago. Diluted earnings per share from continuing operations was USD 30.23 compared to USD 24.57 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

REGN Income Statement

Gross margin TTM 50.75%
Operating margin TTM 29.81%
Net Profit margin TTM 33.61%
Return on Investment TTM 12.46%
 Total Revenue  Net Income
Period Ending: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023
Total Revenue 3720.7 3547.1 3145 3434.3
Gross Profit 1958.1 2944.5 1462.8 1740.1
Operating Income 1243.7 1093.5 758.5 1002.9
Net Income 1340.6 1432.3 722 1159.6

REGN Balance Sheet

Quick Ratio MRQ 4.26
Current Ratio MRQ 5.28
LT Debt to Equity MRQ 6.77%
Total Debt to Equity MRQ 9.22%
 Total Assets  Total Liabilities
Period Ending: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023
Total Assets 37441.9 36086.8 34369.6 33080.2
Total Liabilities 8116 7881 7378.5 7107.1
Total Equity 29325.9 28205.8 26991.1 25973.1

REGN Cash Flow Statement

Cash Flow/Share TTM 39.35
Revenue/Share TTM 128.29
Operating Cash Flow  35.27%
 Cash  Net Change in Cash
Period Ending: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 1291.2 354 1512.5 1089.7
Cash From Investing Activities -574.4 -557.2 -1687.1 -66.2
Cash From Financing Activities -634 -478.1 47.1 -446.1
Net Change in Cash 83.6 -681.6 -128 577.6
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

REGN Comments

Write your thoughts about Regeneron Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Micha Hallande
Micha Hallande Nov 15, 2024 4:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
good news coming ..insider knows
Black Mamba
Black Mamba Jul 02, 2024 7:59PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Oh boy…
Black Mamba
Black Mamba Jul 02, 2024 7:59PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Agreeded the one year looks troubling
Black Mamba
Black Mamba Jul 02, 2024 7:59PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Black Mamba correction i meant 1 month
양 한
양 한 Aug 24, 2023 10:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Scd411 is imminent
Avi Kalo
Avi Kalo Feb 03, 2023 9:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
REGN Earnings are wrong !!! it was 3.41B not M
borat smagadijev
borat smagadijev Jun 09, 2022 3:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Falling knife
Petet Larkar
Petet Larkar Jun 09, 2022 3:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I want your ******
Carmen Esparza
Carmen Esparza Jan 10, 2022 2:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Eliav Biton
Eliav Biton Nov 17, 2021 1:30AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
best opportunity in this market
Financial Advisors
Financial Advisors Nov 04, 2021 6:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
only take long positions .
David Lousada
David Lousada Nov 04, 2021 6:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
huge earnings beat!
Richard Senato
Richard Senato Sep 13, 2021 11:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Whats happening
Marut Patphol
Marut Patphol Sep 13, 2021 11:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Fall
ken ken
ken ken Sep 13, 2021 11:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Most of sales in this quarters are from COVID, and competion announced results
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email